Diffuse Alveolar Hemorrhage in Children with Trisomy 21

Jessica L. Bloom (jessica.bloom@childrenscolorado.org)
Children's Hospital Colorado  https://orcid.org/0000-0002-7645-2084

Benjamin Frank
University of Colorado Denver School of Medicine

Jason P. Weinman
University of Colorado Denver School of Medicine

Csaba Galambos
University of Colorado Denver School of Medicine

Sean T. O'Leary
University of Colorado Denver School of Medicine

Deborah R. Liptzin
University of Colorado Denver School of Medicine

Robert C. Fuhlbrigge
University of Colorado Denver School of Medicine

Research Article

Keywords: pulmonary hemorrhage, diffuse alveolar hemorrhage, Down syndrome, trisomy 21, vasculitis, capillaritis, autoimmune disease, hemoptysis, autoantibodies

DOI: https://doi.org/10.21203/rs.3.rs-297512/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Background: Respiratory conditions are the leading cause of hospitalization and death in children with Trisomy 21 (T21). Diffuse alveolar hemorrhage (DAH) occurs at higher frequency in children with T21; yet, it is not widely studied nor is there a standardized approach to diagnosis or management. The objective of this study was to identify children with T21 and DAH in order to understand contributing factors and identify opportunities to improve outcomes. We identified 5 children with T21 at a single institution with histology-proven DAH over 10 years and discuss their presentation, evaluation, management, and outcomes. We also reviewed the cases in the literature.

Case Presentation: Patient 1 died at age seven due to secondary hemophagocytic lymphohistiocytosis. DAH was seen on autopsy. Patient 2 was a three-year-old with systemic-onset juvenile idiopathic arthritis diagnosed with DAH after presenting for hypoxia. Patient 3 was diagnosed with DAH at age nine after presenting with recurrent suspected pneumonia and aspiration. Patient 4 was diagnosed with DAH at age eight after presenting with pallor and fatigue. She had additional ICU admissions for DAH with infections. Patient 5 developed hemoptysis at age three and had recurrent DAH for ten years. Four patients responded positively to immune-modulation such as intravenous immunoglobulin, glucocorticoids, and rituximab. Of the 19 patients identified in the literature, only one was from the United States. The majority had anemia, respiratory distress, autoantibodies, and recurrences. A minority had hemoptysis. Idiopathic pulmonary hemosiderosis was the most common diagnosis. Almost all received glucocorticoids with or without additional immunosuppression. The majority of our patients and those in the literature had positive auto-antibodies such as anti-neutrophil cytoplasmic antibodies and anti-nuclear antigen antibodies. Diagnostic clues included respiratory distress, hypoxia, anemia, recurrent pneumonia, and/or ground glass opacities on imaging. We identified four contributors to DAH: structural lung abnormalities, pulmonary arterial hypertension, infection/aspiration, and autoimmune disease/immune dysregulation.

Conclusion: These cases demonstrate the need for an increased index of suspicion for DAH in children with T21, enrich the understanding of risk factors, and highlight the favorable response to immunosuppressive therapies in this vulnerable population.

Background

Trisomy 21 (T21; or Down Syndrome) results from complete or partial duplication of chromosome 21. T21 affects 1 in 700 births and is characterized by developmental disability and dysmorphic features. Children with T21 are hospitalized five times more often, with respiratory conditions the leading cause of hospitalization and mortality. Diffuse alveolar hemorrhage (DAH) is a life-threatening cause of respiratory compromise that occurs at increased frequency in children with T21.

DAH occurs when blood enters the alveolar spaces due to a disturbance of the alveolar-capillary basement membrane and can result in respiratory failure and death. The diagnosis may be delayed or missed in children, as many do not expectorate blood and have non-specific findings on imaging. In one study, two-thirds of children with DAH were initially misdiagnosed, most often with pneumonia. Definitive diagnosis is made via bloody fluid return, microscopic red blood cells, or hemosiderin-laden macrophages on bronchoalveolar lavage (BAL) or alveolar hemorrhage or hemosiderin on lung histology. Treatment decisions such as glucocorticoids, antimicrobials, and/or vasoactive medications often precede diagnosis and may be counterproductive.

A 2018 study utilizing the French RespiRare Network found that nine of 34 pediatric patients with DAH of unknown etiology (i.e. idiopathic pulmonary hemosiderosis) from 1997–2017 also had T21, estimating a 75-fold higher prevalence in children with T21. Children with T21 had earlier onset, more severe respiratory distress, less hemoptysis, and increased morbidity and mortality. The reasons for this are neither well understood nor widely studied.

Here, we report five DAH cases in children with T21 at one center and a review of the literature. We aim to increase awareness of this life-threatening condition, highlight how it presents in this population, and identify opportunities to improve outcomes.

Case Presentations

Eleven children with DAH and T21 were identified in one institution's histopathology database and summarized via chart review. Six were excluded due to disseminated intravascular coagulation, trauma, and/or perinatal causes. All five remaining patients were Caucasian. Additional details are listed below and in Table 1. Additionally, a literature review was conducted of all published cases.

Patient 1 was born at 35 weeks gestation with a tracheoesophageal fistula and later developed asthma. He presented at age six with fever, rash, arthralgia, and severe anemia. Symptoms persisted until he died at age seven due to secondary hemophagocytic lymphohistiocytosis. Lung histology at autopsy revealed DAH, abnormal alveolar growth, moderate pulmonary artery thickening, a double capillary layer, and focal interstitial fibrosis.

Patient 2 was born at 40 weeks gestation with an atrioventricular septal defect (AVSD) and duodenal atresia. At age two, she developed systemic juvenile idiopathic arthritis managed with anakinra. She was admitted for hypoxia at age three. Chest computed tomography (CT) demonstrated subpleural cystic lucencies, ground glass opacities, atelectasis, and small pleural effusions. BAL showed acute inflammation and bloody fluid return. Lung biopsy revealed DAH, abnormal alveolar growth, moderate pulmonary artery thickening, focal pneumonia, cholesterol clefts, and subpleural type 2 cell proliferation. Echocardiogram demonstrated mild pulmonary arterial hypertension (PAH). She remained on anakinra and 0.5 L/min of oxygen three months later and was lost to follow-up.

Patient 3 was born at 36 weeks gestation with a laryngeal cleft and AVSD. She presented for pulmonary evaluation at age nine due to recurrent suspected pneumonia, chronic aspiration, and obstructive sleep apnea (OSA). Chest CT demonstrated diffuse ground glass opacities, cystic lucencies, septal thickening, and atelectasis. BAL showed elevated hemosiderin-laden macrophages. Lung biopsy revealed DAH, abnormal alveolar growth, moderate pulmonary artery thickening, and airway damage (Fig. 1). She started monthly intravenous immunoglobulin (IVIG) infusions and daily glucocorticoids. Biopsy after 6 months...
showed plasma cells and CD3+ T lymphocytes concerning for immune dysregulation. BAL after 12 months had persistent red blood cells. IVIG and glucocorticoids were stopped after 20 months without further DAH.

Patient 4 was born at 39 weeks gestation with an AVSD, galactokinase deficiency, prothrombin gene mutation, and left atrioventricular valve insufficiency. She developed OSA, sinusitis, and recurrent pneumonia in early childhood and underwent mitral valve repair at age eight. She presented with fatigue and pallor one month later and was diagnosed with DAH. At age nine, she presented to this hospital after a year of recurrent hemorrhages. Lung biopsy revealed DAH, abnormal alveolar growth, moderate pulmonary artery thickening, and a double capillary layer; rare interstitial and pleural perivascular neutrophils signaled possible resolving capillaritis. She received IV methylprednisolone and rituximab therapy followed by two years of IVIG and glucocorticoids. Repeat biopsy at 11 showed pulmonary hemosiderosis. At 13 and 16, she required ICU admission and IV glucocorticoids for DAH with influenza B and human metapneumovirus, respectively. She re-started rituximab during the second admission. Chest CTs demonstrated diffuse centrilobular nodules, ground glass opacities, septal thickening, and mild cystic lucencies (Fig. 2). BAL showed bloody fluid return. She remains on rituximab.

Patient 5 was born at 26 weeks gestation and developed bronchopulmonary dysplasia, aspiration, hypothyroidism, aortic and tricuspid valve insufficiency, and mild PAH. She developed recurrent hemoptysis at age three and began daily prednisone. Chest CT demonstrated diffuse ground glass opacities and cystic lucencies. BAL revealed hemosiderin-laden macrophages. Lung biopsy showed DAH, abnormal alveolar growth, and moderate pulmonary artery thickening. She remained on steroids for a decade due to recurrent hemoptysis. At 14, she presented to this hospital for evaluation. Steroids were discontinued. The next year, chest CT demonstrated diffuse ground glass opacities despite unremarkable BAL. Chest CT showed resolved opacities one year later.

Review of the literature identified fewer than ten published, English-language cases of DAH in children with T21 outside of the RespiRare study and only one from the United States (Table 2).

Discussion And Conclusions

These cases emphasize the variety of ways in which DAH presents in children with T21. The reasons for increased risk are multifactorial but likely include the following:

1. **Structural lung abnormalities** may increase risk of DAH. Children with T21 have alveolar simplification, which is often compounded by prematurity. Children with T21 are also at risk for vascular abnormalities, such as left-to-right shunts and persistent double capillary networks.

2. **PAH** may lead to DAH through increased hydrostatic pressure, vasodilator adverse effects, or aneurysmal rupture. At least 25% of children with T21 have PAH due to issues such as abnormal vascular walls, OSA, and heart disease. Three of our patients had echocardiograms showing pulmonary hypertension and all had pulmonary artery thickening on histology.

3. **Infection and aspiration** may increase the risk for DAH and are more prevalent in children with T21. The similarity of radiographs and symptoms in these three conditions may lead to missed or delayed diagnosis of DAH.

4. **Autoimmune disease and immune dysregulation** may increase risk of DAH and are more prevalent in children with T21. Celiac disease, for instance, has a 6–10 fold higher frequency in children with T21 and is associated with increased risk of DAH. Children with T21 have altered innate and adaptive immune responses and a higher prevalence of autoantibodies. Within our cohort, one patient had secondary hemophagocytic histiocytosis, one had systemic JIA and three had autoantibodies of unknown significance.

Our data shows that DAH should be considered in children with T21 in the setting of respiratory distress, hypoxia, anemia, and/or ground glass opacities on imaging. Inflammatory markers may or may not be elevated and autoantibodies are often present. Hemoptysis was infrequent and cannot be relied on for diagnosis, while misdiagnosis of recurrent pneumonia often led to diagnostic delay. Diagnosis and management often involve both pulmonologists and rheumatologists.

Most patients within our cohort and the literature responded to immunomodulating therapies such as steroids, IVIG, and rituximab, supporting immune dysregulation as an etiology of DAH. Our patients lacked clear immune-mediated pulmonary capillaritis on lung histology; however, all samples were obtained after exposure to glucocorticoids and may have had an attenuated inflammatory response.

This series is limited by its retrospective focus at one institution; however, five patients over a 10-year period is a robust sample when compared to the literature. Our hospital cares for approximately 1600 children with T21 from a catchment area of 9.5 million children. Based on the French estimates for DAH in T21, we would expect only one to two patients with T21 to have DAH in our population, suggesting that the true prevalence may be even higher.

Underestimation of prevalence is also likely influenced by a low index of suspicion among providers. Many patients with T21 and respiratory symptoms do not undergo CT imaging, bronchoscopy, or lung biopsy and therefore DAH may be missed. Additionally, while these cases report the presence of autoantibodies and/or structural variations, it is not possible to confirm their direct role in DAH development. Further characterization of this population through a larger, multi-institutional sample will better define the spectrum of disease and guide care.

In summary, we recommend an increased index of suspicion for DAH among children with T21 who present with respiratory symptoms. Providers should have a low threshold to evaluate for anemia and autoimmune pathology and consider pursuing additional imaging or procedures. Improved awareness of DAH in children with T21 will allow for earlier detection and reduce morbidity and mortality in this vulnerable population.

Abbreviations
Trisomy 21 (T21), Diffuse Alveolar Hemorrhage (DAH), Bronchoalveolar lavage (BAL), Atrioventricular septal defect (AVSD), Chest computed tomography (CT), Pulmonary arterial hypertension (PAH), Obstructive sleep apnea (OSA), Intravenous immunoglobulin (IVIG), Atrioventricular Valve (AV), Anti-neutrophil cytoplasmic antibody (ANCA), Anti-myeloperoxidase antibody (MPO), Anti-serine protease 3 antibody (PR3), Systemic Juvenile Idiopathic Arthritis (SJIA), Anti-Sjogrens-Syndrome-related antigen A (SSA), Anti-Ribonucleoprotein (RNP), Anti-Cyclic-Citrullinated Peptide (CCP), Rheumatoid Factor (RF), Intensive Care Unit (ICU), Anti-nuclear antigen (ANA), Immunoglobulin E to Cow's Milk Protein IgE-CMP), Idiopathic Pulmonary Hemosiderosis (IPH), ANCA-Associated Vasculitis (AAV), Anti-double stranded DNA antibody (dsDNA), Immunoglobulin D (IgD), Ventricular Septal Defect (VSD), Atrial Septal Defect (ASD), Patent Ductus Arteriosus (PDA), Glomerular Basement Membrane (GBM), Tissue Transglutaminase Immunoglobulin A Antibody (TTG-IgA), Perinuclear ANCA (pANCA)

Declarations

Ethics approval and consent to participate: Approved by the Colorado Multiple Institutional Review Board under Protocol 10-0472.

Consent for publication: No identifying data or images used.

Availability of data and material: Not Applicable.

Competing interests: None

Funding: All phases of this study were supported by an NIH grant, T32 AR007534. Dr. Csaba Galambos is supported by a grant from the Linda Crnic Institute for Down Syndrome, University of Colorado.

Authors’ contributions:

Jessica Bloom MD: Dr. Bloom provided medical care for Patient 4, conceptualized the project with the team, drafted the initial manuscript, finalized the figures and tables, confirmed revisions, and approved and submitted the final manuscript.

Benjamin Frank MD: Dr. Frank helped develop the project with the team, provided reviewed the echocardiograms for all patients, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Jason P. Weinman MD: Dr. Weinman conceptualized the project with the team, reviewed the imaging for all patients, provided images for Figure 2, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Csaba Galambos MD PhD: Dr. Galambos conceptualized the project with the team, reviewed the pathology for all patients, provided images for Figure 1, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Sean T. O’Leary MD: Dr. O’Leary provided medical care for patient 2, conceptualized the project with the team, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Deborah R. Liptzin MD: Dr. Liptzin provided medical care for patients 3, 4 and 5, conceptualized the project with the team, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Robert Fuhlbrigge MD PhD: Dr. Fuhlbrigge conceptualized the project with the team, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Acknowledgements: Thank you to Dr. Joaquin Espinosa and Dr. Angela Rachubinski of the Human Trisome Project and Linda Crnic Institute for Down Syndrome for their collaboration.

References

1. Saji T. Clinical characteristics of pulmonary arterial hypertension associated with Down syndrome. Pediatr Int. 2014;56(3):297–303.
2. Fitzgerald P, Leonard H, Pikora T, Bourke J, Hammond G. Hospital admissions in children with down syndrome: experience of a population-based cohort followed from birth. PLoS One. 2013;8(8):e70401.
3. Joffre C, Lesage F, Bustarre O, Hubert P, Ouallah M. Children with Down syndrome: Clinical course and mortality-associated factors in a French medical paediatric intensive care unit. J Paediatr Child Health. 2016;52(6):595–9.
4. Hilton J, Fitzgerald D, Cooper D. Respiratory morbidity of hospitalized children with Trisomy 21. J Paediatr Child Health. 1999;35:383–6.
5. Bruijn M, van der Aa LB, van Rijn RR, Bos AP, van Woensel JB. High incidence of acute lung injury in children with Down syndrome. Intensive Care Med. 2007;33(12):2179–82.
6. Parris D, Van Niekerk A, Jeevarathnum A, Green R. An approach to pulmonary haemorrhage in children. S Afr Respir J. 2017;23(3):63–70.
7. Alimi A, Taytard J, Abou Taam R, et al. Pulmonary hemosiderosis in children with Down syndrome: a national experience. Orphanet J Rare Dis. 2018;13(1):60.
8. Zhang Y, Luo F, Wang N, Song Y, Tao Y. Clinical characteristics and prognosis of idiopathic pulmonary hemosiderosis in pediatric patients. J Int Med Res. 2019;47(1):293–302.
9. Park MS. Diffuse alveolar hemorrhage. Tuberc Respir Dis (Seoul). 2013;74(4):151–62.
10. Hori I, Nakaseko H, Kamei M, et al. Diffuse alveolar hemorrhage secondary to ANCA-associated vasculitis in a patient with Down syndrome. Pediatr Int. 2015;57(2):e45–7.
11. Rayment J, Cutz E, Levy D, Dell S. Concomitant Diffuse Alveolar Hemorrhage and Pulmonary Embolism in a Child with Isolated Pulmonary Capillaritis. AnnalsATS. 2017;14(3):470–2.
12. Watanabe H, Ayusawa M, Kato M, et al. Idiopathic pulmonary hemosiderosis complicated by Down syndrome. Pediatr Int. 2015;57(5):1009–12.
13. Galant S, Nussbaum E, Wittner R, DeWeck AL, Heiner DC. Increased IgD milk antibody responses in a patient with Down's syndrome, pulmonary hemosiderosis and cor pulmonale. Ann Allergy. 1983;51(4):446–9.
14. Aceti A, Sciuitti R, Bracci P, Bertelli L, Melchionda F, Cazzato S. Idiopathic pulmonary haemosiderosis in a child with Down's syndrome: case report and review of the literature. Sarcoidosis Vasculitis Diffuse Lung Diseases. 2011;28:58–61.
15. Schwab M, Boswald M, Ludwig K, Wittekind C, Waldherr R, Ruder H. A patient with Down's syndrome and anti-neutrophilic cytoplasmic antibody-positive vasculitis. Pediatr Nephrol. 1996;10(2):249–50.
16. Niimi A, Aimitani R, Kurasawa T, et al. Two cases of idiopathic pulmonary hemosiderosis: analysis of chest CT findings. Nihon Kyobu Shikkan Gakkai Zasshi. 1992;30(9):1749–55.
17. Sato YNI, Saeki Y. A case report of Idiopathic pulmonary haemosiderosis in a child with Down syndrome (Japanese only). 1986.
18. Koyama T, Tenou H, Kanadani T, Murakami M. A case of Down syndrome complicated with idiopathic pulmonary hemosiderosis. IRYO. 1995;49(7):580–3.
19. McDowell KM, Craven DI. Pulmonary complications of Down syndrome during childhood. J Pediatr. 2011;158(2):319–25.
20. Mak SM, Strickland N, Gopalan D. Complications of pulmonary hypertension: a pictorial review. Br J Radiol. 2017;90(1070):20160745.
21. Bush D, Galambos C, Ivy DD, Abman SH, Wolter-Warmerdam K, Hickey F. Clinical characteristics and risk factors for developing pulmonary hypertension in children with Down Syndrome. J Pediatr. 2018;202:212–9 e212.
22. Verstegen RHJ, Chang KJJ, Kusters MAA. Clinical implications of immune-mediated diseases in children with Down syndrome. Pediatr Allergy Immunol. 2020;31(2):117–23.
23. Fisher BA, Charles P, Lundberg K, Gillespie KM, Newton RW, Venables PJ. Organ-specific autoantibodies but not anti-cyclic citrullinated peptides are a feature of autoimmunity in Down's syndrome. Ann Rheum Dis. 2010;69(5):939–40.
24. da Rosa Utiyama SR, Nishara RM, Nass FR, Oliveira NP; Fiedler PT, de Messias-Reason IT. Autoantibodies in patients with Down syndrome: early senescence of the immune system or precocious markers for immunological diseases? J Paediatr Child Health. 2008;44(4):182–6.
25. Gimenez-Barcons M, Casteras A, Armengol Mdel P, et al. Autoimmune predisposition in Down syndrome may result from a partial central tolerance failure due to insufficient intrathymic expression of AIRE and peripheral antigens. J Immunol. 2014;193(8):3872–9.
26. Powers RK, Culp-Hill R, Ludwig MF; et al. Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. Nat Commun. 2019;10(1):4766.

**Tables**

**Table 1. Case Descriptions**
| Presentation | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|--------------|-----------|-----------|-----------|-----------|-----------|
| **Sex**      | Male      | Female    | Female    | Female    | Female    |
| **Age at 1st known DAH (years)** | 7 | 3 | 9 | 8 | 3 |
| **Presenting Symptoms** | Fever, rash, joint pain, respiratory failure | Persistent oxygen requirement | Recurrent pneumonia and aspiration | Respiratory Distress, Hypoxia | Hemothypsis |
| **Hemothypsis** | No | No | No | No | Yes |
| **Laboratory Result* White Blood Cell Count** | H | N | N | U | N |
| **Hemoglobin** | L | L | H | L | N |
| **Platelets** | L | N | N | U | N |
| **Inflammatory Markers** | | | | | |
| **Erythrocyte Sedimentation Rate** | H | H | N | U | N |
| **C-reactive Protein** | H | H | N | U | U |
| **Ferritin** | H | H | U | U | U |
| **Antibodies†** | Positive | - | - | C-ANCA, MPO | MPO |
| **Negative** | ANCA, ANA | - | ANA, Anti-GBM | ANCA, PR3, ANA | - |
| **Creatinine** | H | U | U | U | U |
| **Investigations**** Echocardiogram** | ND | Mild PAH | Mild PAH, AV regurgitation | Mild PAH, AV regurgitation and stenosis | ND |
| **Bronchoscopy with BAL** | ND | Bloody fluid return | Hemosiderin-Laden Macrophages | Bloody fluid return | Hemosiderin-Laden Macrophages |
| **Chest CT** | ND | Y | Y | Y | Y |
| **Ground Glass Opacities** | - | Y | Y | Y | Y |
| **Cystic Lucencies** | - | Y | Y | Y | Y |
| **Other Findings** | - | Atelectasis, small pleural effusions | Atelectasis, septal thickening | Diffuse centrilobular nodules, septal thickening | - |
| **Lung Biopsy‡** | Φ | | | | |
| **Alveolar Hemorrhage** | Mild | Mild | Marked | Mild | Moderate |
| **Hemosiderin** | Mild | Moderate | Marked | Minimal | |
| **Abnormal Alveolar Growth** | Y | Y | Y | Y | Y |
| **Pulmonary Artery Thickening** | Moderate | Moderate | Moderate | Moderate | Moderate |
| **Other Findings** | Double capillary layer, focal interstitial fibrosis | Focal pneumonia, cholesterol clefts, subpleural type 2 cell proliferation | Airway Damage (repeat biopsy with plasma cell/CD3+ lymphocytes) | Double capillary layer, rare interstitial and pleural perivascular neutrophils | - |
| Treatment | Y | Y | Y | Y | Y |
|-----------|---|---|---|---|---|
| Glucocorticoids | Antibiotics | Continued anakinra for SJIA | IVIG | IVIG, Rituximab | - |
| Other Medications | Deceased | Remained on 0.5 L/min of oxygen via nasal cannula 3 months later, then lost to follow up | Repeat BAL with red blood cells 1 year later. Therapy stopped after 20 months, no recurrences. | 2 recurrences requiring ICU admission (one with Influenza B, one with Human Metapneumovirus) | Recurrences through age 14, then lost to follow up |

Abbreviations: Diffuse Alveolar Hemorrhage (DAH), Pulmonary Arterial Hypertension (PAH), Atrioventricular Valve (AV), Anti-neutrophil cytoplasmic antibody (ANCA), Anti-myeloperoxidase antibody (MPO), Anti-serine protease 3 antibody (PR3), Bronchoalveolar lavage (BAL), Systemic Juvenile Idiopathic Arthritis (SJIA), Intravenous Immunoglobulin (IVIG), Anti-Sjogrens-Syndrome-related antigen A (SSA), Anti-Ribonucleoprotein (RNP), Anti-Cyclic-Citrullinated Peptide (CCP), Rheumatoid Factor (RF), Intensive Care Unit (ICU)

*H = High, L = Low, N = Normal, U = Unknown
†Not listed or ( ) = unknown
**Y = Yes, N = No, ND = Not Done
‡All performed after exposure to glucocorticoids
ΦHistopathology from autopsy

Table 2. Literature Review
| Author, Year published | Sex | Ethnicity | Comorbidities in addition to T21 | Age at 1st DAH (years) | Presenting Symptoms | Known Antibody Testing* | Diagnosis | Treatment | Outcome |
|------------------------|-----|-----------|---------------------------------|------------------------|---------------------|-------------------------|-----------|-----------|---------|
| Alimi, 2018*\(^1\)    | 4 F, 5 M | French | 3 with PAH, 3 with cardiopathy | Mean: 2.92 +/- 3.45 | 2 with hemoptysis, all with dyspnea, 6 with hemoglobin < 7 | 6 with antibodies: ANCA, ANA, CCP, PR3, MPO, TTG-IgA, IgE-CMP | IPH | All: glucocorticoids | 3 without relapse |
| Zhang, 2019*\(^2\)    | - Chinese | - | - | 1 of 107 children hospitalized with IPH at a single institution over a 21 year period | - | IPH | - | - | - |
| Hori, 2015*\(^3\)     | F Japanese | PAH, history of Kawasaki disease | 2 | Pallor, anorexia, dyspnea, hemoptysis, nephritis | +MPO | AAV | azathioprine, glucocorticoids | Improved, stat time of publica |
| Rayment, 2017*\(^5\)  | F | - | Repaired AVSD | 2.5 | Respiratory distress, anemia, thrombocytopenia | +ANCA | Isolated pulmonary capillaritis, bilateral pulmonary embolisms | glucocorticoids, rituximab, azathioprine | Improved, stat at least 2.5 ye |
| Watanabe, 2015*\(^6\) | F Japanese | Hypothyroidism, autism | 9 | Cough, emesis of bloody sputum, hypoxemia, fatigue | +ANA, dsDNA | IPH | glucocorticoids | Recurred with hemoptysis 2 weeks later, th stable at least months |
| Galent, 1983*\(^7\)   | M African American | PAH | 2 | Respiratory distress, blood-streaked sputum, fever, nasal discharge, cough | Elevated IgD antibody to milk proteins | Milk-related pulmonary hemosiderosis and cor pulmonale | Removal of cow's milk from diet | Symptoms resolved. Re-introduction a removal repea pattern. |
| Aceti, 2012*\(^8\)    | F Italian | History of VSD, ASD, PDA, necrotizing enterocolitis | 4 | Recurrent anemia and respiratory distress, hemoptysis | Negative ANA, ANCA, anti-GBM, TTG-IgA | Idiopathic Pulmonary Hemosiderosis | glucocorticoids | Recurred within months; adder hydroxchloro recurred withi year |
| Schwab, 1996*\(^9\)   | M German | - | 6 | Recurrent pneumonia, hemoptysis, anemia, renal failure | +pANCA | AAV | glucocorticoids, cyclophosphamide | No recurrence years |
| Niimi, 1992*\(^10\)   | F VSD | - | 17 | Dyspnea | +ANA | Negative RF, Anti-GBM | glucocorticoids | 3 recurrences years |
| Sato, 1986*\(^11\)    | F Japanese | - | 3 | Cough, wheeze, anemia | - | - | azathioprine, disodium cromoglycate inhalation, milk avoidance | 7 recurrences year |
| Koyama, 1995*\(^12\)  | F Japanese | - | 9 | Fever, dyspnea, anemia, pallor | - | IPH | glucocorticoids | No recurrence months |

\(*\) = unknown

*if unlisted, test is unknown.

Abbreviations: Pulmonary Arterial Hypertension (PAH), Anti-neutrophil cytoplasmic antibody (ANCA), Anti-nuclear antigen (ANA), Anti-Cyclic Citrullinated Peptide Antibody (CCP), Serine Protease 3 antibody (PR3), Anti-Myeloperoxidase Antibody (MPO), Immunoglobulin E to Cow’s Milk Protein (IgE-CMP), Idiopathic Pulmonary Hemosiderosis (IPH), ANCA-Associated Vasculitits (AAV), Atrioventricular Septal Defect (AVSD), Anti-double stranded DNA antibody
(dsDNA), Immunoglobulin D (IgD), Ventricular Septal Defect (VSD), Atrial Septal Defect (ASD), Patent Ductus Arteriosus (PDA), Glomerular Basement Membrane (GBM), Tissue Transglutaminase Immunoglobulin A Antibody (TTG-IgA), Perinuclear ANCA (pANCA), Rheumatoid Factor (RF)

**Figures**

**Figure 1**

Lung biopsy findings in a 11-year-old female with trisomy 21 (Patient 3). A: Low power view shows areas of alveolar hemorrhage (black arrows) and hemosiderin laden macrophages (white arrows). Hematoxylin-eosin stain, 4x. B: High power view shows a moderately remodeled pulmonary artery (arrow points to pathologically muscularized arteriolar wall). Hematoxylin-eosin stain, 20x. C: High power view shows hemorrhage, hemosiderin laden macrophages within simplified and distended alveoli (example is white dotted). A rare neutrophil (black arrow) is seen in the alveolar interstitium, not diagnostic of capillaritis. Hematoxylin-eosin stain, 20x. D: The inflammatory infiltrate on repeat biopsy is mainly composed of lymphocytes, but rare plasma cells are noted (black arrow), 40x. E: The majority of lymphocytes on repeat biopsy are marked by a T-cell immunomarker CD3, 40x.

![Figure 1](image1)

**Figure 2**

Chest CT findings in a 13-year-old female with trisomy 21 (Patient 4). Axial CT images through the upper (A) demonstrate ill-defined nodular ground glass opacities in the left upper lobe (arrows). Axial CT image through the lower chest (B) demonstrates innumerable tiny centrilobular nodules and septal thickening bilaterally.

![Figure 2](image2)